Free Trial

Autolus Therapeutics (AUTL) Competitors

Autolus Therapeutics logo
$2.52 -0.12 (-4.55%)
Closing price 04:00 PM Eastern
Extended Trading
$2.57 +0.05 (+1.98%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AUTL vs. RARE, ALVO, AMRX, MIRM, CPRX, ARWR, IBRX, OGN, APLS, and XENE

Should you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

Autolus Therapeutics vs. Its Competitors

Autolus Therapeutics (NASDAQ:AUTL) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Autolus Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Autolus Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autolus Therapeutics$9.01M74.43-$220.66M-$0.88-2.86
Ultragenyx Pharmaceutical$590.69M4.38-$569.18M-$5.88-4.65

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Autolus Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Autolus Therapeutics' return on equity of -52.82% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Autolus TherapeuticsN/A -52.82% -29.67%
Ultragenyx Pharmaceutical -93.04%-186.49%-36.81%

Autolus Therapeutics currently has a consensus price target of $9.32, suggesting a potential upside of 269.84%. Ultragenyx Pharmaceutical has a consensus price target of $83.64, suggesting a potential upside of 205.94%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Autolus Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ultragenyx Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

In the previous week, Autolus Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 7 mentions for Autolus Therapeutics and 5 mentions for Ultragenyx Pharmaceutical. Autolus Therapeutics' average media sentiment score of 0.52 beat Ultragenyx Pharmaceutical's score of -0.21 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Autolus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ultragenyx Pharmaceutical
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Autolus Therapeutics beats Ultragenyx Pharmaceutical on 13 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AUTL vs. The Competition

MetricAutolus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$670.68M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-2.8621.1828.1120.03
Price / Sales74.43337.65460.63103.88
Price / CashN/A43.2336.5559.01
Price / Book1.578.368.655.90
Net Income-$220.66M-$55.19M$3.25B$258.66M
7 Day Performance4.56%5.89%4.20%2.23%
1 Month Performance8.62%17.63%10.83%12.77%
1 Year Performance-45.22%5.10%34.67%19.36%

Autolus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AUTL
Autolus Therapeutics
2.6099 of 5 stars
$2.52
-4.5%
$9.32
+269.8%
-38.5%$670.68M$9.01M-2.86330
RARE
Ultragenyx Pharmaceutical
4.35 of 5 stars
$29.23
-0.9%
$83.64
+186.2%
-39.5%$2.76B$560.23M-4.971,294Upcoming Earnings
High Trading Volume
ALVO
Alvotech
2.8352 of 5 stars
$8.90
+4.5%
$18.00
+102.2%
-21.0%$2.68B$585.60M24.051,032
AMRX
Amneal Pharmaceuticals
3.1369 of 5 stars
$8.42
+1.1%
$11.60
+37.8%
+8.0%$2.64B$2.79B-210.458,100
MIRM
Mirum Pharmaceuticals
3.8597 of 5 stars
$53.28
+1.2%
$65.50
+22.9%
+33.5%$2.64B$336.89M-33.09140
CPRX
Catalyst Pharmaceuticals
4.9202 of 5 stars
$21.62
-0.9%
$32.83
+51.9%
+20.0%$2.64B$491.73M13.7780News Coverage
Positive News
Analyst Revision
ARWR
Arrowhead Pharmaceuticals
3.782 of 5 stars
$18.61
+1.6%
$43.71
+134.9%
-43.8%$2.57B$545.21M-13.29400News Coverage
Positive News
IBRX
ImmunityBio
2.1313 of 5 stars
$2.90
+3.2%
$12.25
+322.4%
-43.5%$2.56B$31.22M-5.00590News Coverage
Analyst Forecast
OGN
Organon & Co.
4.7689 of 5 stars
$9.83
-1.2%
$18.00
+83.2%
-53.5%$2.55B$6.40B3.414,000
APLS
Apellis Pharmaceuticals
4.2398 of 5 stars
$19.91
+2.4%
$39.79
+99.8%
-46.3%$2.50B$781.37M-11.12770Upcoming Earnings
XENE
Xenon Pharmaceuticals
3.7513 of 5 stars
$32.60
+1.2%
$54.82
+68.2%
-29.1%$2.50B$9.43M-10.09210Positive News
Options Volume

Related Companies and Tools


This page (NASDAQ:AUTL) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners